جستجوی مقالات مرتبط با کلیدواژه "interferon beta 1a" در نشریات گروه "پزشکی"

Glatiramer acetate (GA) and Interferon (IFN) beta-1a are used as first-line disease-modifying treatments for multiple sclerosis (MS). In this systematic review, we summarized case reports and case series of adverse side effects of GA and IFN beta-1a in MS patients.

Without any restrictions, PubMed, Scopus, Web of Sciences, and Embase databases, and gray literature were systemically searched until June 2022. Articles were screened and data were extracted based on a predefined table by two independent reviewers. The risk of bias was assessed using the Joanna Briggs Institute (JBI) tool.

We identified 2103 records from the preliminary search. After deduplication and screening, 172 articles were included in the systematic review. In total, 229 individuals (52 men, 173 women, and 4 unknown) were included in the study. The most common adverse events were cutaneous (32.75%), hepatic (13.54%), allergic (8.3%), and neurological (5.68%) side effects. Furthermore, most reported side effects were related to autoimmune diseases or hypersensitivity reactions.

GA and IFN beta-1a are associated with several side effects which may be related to the immunomodulatory function of medication or other injection-related reactions.

Since December 2019, an outbreak of Covid-19 has caused growing concern in multiple countries. Researchers around the world are working to find a treatment or a vaccine for Covid-19 and different treatment approaches have been tested in this regard. 

This study was designed and conducted to assess the possible efficacy of Interferon beta-1a as a safe and efficient candidate for Covid-19 treatment. 

This is an investigator-initiated, open-label, single-arm clinical trial. Twenty patients with suspected Covid-19, who were admitted to Sina hospital in Tehran, Iran, with moderate to severe symptoms, from 6 to 10 March, 2020, were enrolled. Patients were treated with antiviral and hydroxychloroquine combination therapy, along with subcutaneous Interferon beta-1a for 5 consecutive days. Baseline characteristics and findings during the course of admission and 5 days after discharge were recorded for all the patients. 

In total, 20 patients with suspected Covid-19 were included in this study, 12 (60%) of which were male. The median (Interquartile (IQ) range) of patients’ age was 55.5 (43-63.5). The most common symptom of the patients at onset of disease was fever. The median (IQ range) of duration of hospital stay was 5.0 (3-6) days. Only 2 cases were admitted to ICU. At the time of follow-up, 15 (94%) patients reported that they generally felt good and had oral tolerance, 1 patient had suffered from dyspnea, 5 patients had suffered from cough, none of them had experienced fever and no case of re-admission or death was reported after discharge. 

Results of the current study are in favor of using Interferon beta-1a in addition to recommended antiviral treatment in Covid-19 patients.

IFN beta-1a is a recombinant protein which reduces the symptoms of Multiple Sclerosisdisease. The purpose of this study was comparison the effects of gamma irradiation and acid pH methods on the biological attributes of recombinant protein IFN beta-1a in order to viral inactivation.

IFN beta was produced by recombinant-DNA in CHO Cell line which include human IFN beta gene and divided in two parts. The acidity of one part was adjusted about pH=4 by hydrochloric acid and incubated two hours, then was returned back to initial pH=7 by NaoH (1 M). The second part was irradiated by a Nordian model 220 gamma irradiator, with different doses: 10, 25 and 50 kGy. The prepared samples with both methods were analyzed by SDS-PAGE and HPLC.

The HPLC indicated decreasing in purity and protein content of gamma irradiated samples, whereas these properties for the acidic pH treated sample was the same as the standard sample. Aggregation of gamma irradiated IFN beta-1a protein and increasing of the protein molecular weight were shown by SDS-PAGE, but it was without any change in molecular weight (22.5 KDa) at acidic pH sample. Also, decreasing of IFN beta antiviral activity through decreasing its concentration has been shown via antiviral assay.

The low pH method can be used for viral inactivation without any change in structure and biological activity of IFN beta-1a but the results indicated differences between the irradiated and standard samples, whereas the acidic pH treated sample was the same as the standard.

Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to its higher price, this study aimed to evaluate the cost-effectiveness of PEG-interferon beta 1-a compared with interferon beta 1a from an Iranian payer perspective. A Markov model was designed according to health states based on Expanded Disability Status Scale (EDSS) and one-month cycles over a 10-year time horizon. Direct medical and non-medical costs were included from a payer perspective. The incremental cost-effectiveness ratio (ICER) was estimated around 11111 US dollars (USD) per quality-adjusted life-year (QALY) gained for the PEG-interferon versus interferon regimen [with currency rate of 29,000 Iranian Rial (IRR) to 1 USD in 2016]. Considering the cost-effectiveness threshold in Iran [three times of gross domestic product (GDP) per capita or 15,945 USD], PEG-interferon beta 1-a could be considered as a cost effective treatment for Iranian patients with MS

Interferons are some kind of natural cytokines which express in response to a variety of antigens including viral RNA, bacterial products, and tumor proteins. Interferon beta is used in the treatment of autoimmune diseases such as multiple sclerosis. Moreover, this drug inhibits cellular proliferation as well as angiogenesis and as a result, helps to cure cancer. In this research, in addition to cloning the interferon-beta gene along with conserved kozak sequence after the strong eEf1a promoter in the pBud.CE4.1 vector, the expression of this recombinant gene was compared to basal expression in HEK293T cell line using real-time PCR, SDS PAGE and western blot tests.
In the beginning, the interferon-beta gene was amplified from the pSVM dhfr vector containing the gene, using primers including BglII and KpnI restriction sites as well as conserved kozak sequence. Then the duplicated gene was digested and inserted in the linear pBud.CE4.1 vector. After ensuring entry of the gene using RFLP, colony PCR and sequencing, the recombinant vector was transfected into E. coli TOP10 competent bacteria. After that, amplified recombinant vector was extracted and transfected into HEK293 cell line.
The expression of interferon-beta cloned in pBud.CE4.1 vector showed a 79.9-fold increase, in comparison with the basal expression in HEK293T cell line. Moreover, non-recombinant vector transfection has increased the expression of interferon-beta up to 2.87 times in the cell line that is probably due to the existence of the viral promoter in the vector.
Real-time PCR and protein test results showed that recombinant beta interferon gene had been successfully expressed in HEK293T cell line. In order to produce more of this protein, optimization of various conditions are required for the HEK293T cell line.

Cinnovex is a biosimilar form of intramuscular (IM) interferon beta-1a (IFNβ-1a) manufactured in Iran for management of multiple sclerosis (MS). The present study aimed to determine the cost-utility of Cinnovex versus Avonex for patients with relapsing-remitting MS (RRMS) from Iranian health ministry perspective.
A Markov model was developed to determine 10-year cost and quality-adjusted life-years (QALYs) of patients with transition through health states based on Kurtzke Expanded Disability Status Scale (EDSS). To estimate the cost of each method, we inquired the subsidies allocated to Avonex and Cinnovex by Iran’s health ministry. Moreover, to estimate the quality of life (QOL) of patients in each group, a cross-sectional study was conducted among two groups of patients who had used Avonex and Cinnovex (n = 50 and n = 50, respectively), using the multiple sclerosis quality of life-54 (MSQOL-54) questionnaire. Finally, one-way sensitivity analysis (tornado diagram) was performed in order to examine the strength of the results.
According to results, the estimated 10-year discounted cost per patient for Avonex and Cinnovex were 21346.5 international dollar ($Int) and 47436.6 $Int, respectively; while the estimated total discounted QALYs per person were 3.76 and 3.89, respectively. The incremental cost per QALY for Cinnovex compared with Avonex was 162718.55 $Int.
It is concluded that Cinnovex in patients with progressive relapsing MS is cost-effective associated with increased benefits compared with Avonex.